The Ile164 beta2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure.
about
An asn to lys polymorphism in the third intracellular loop of the human alpha 2A-adrenergic receptor imparts enhanced agonist-promoted Gi couplingPharmacogenetics in chronic heart failure: new developments and current challengesThe effect of the beta(2) adrenoceptor gene Thr164Ile polymorphism on human adipose tissue lipolytic functionBeta-2 adrenergic receptor gene polymorphisms Gln27Glu, Arg16Gly in patients with heart failure.Dual modulation of cell survival and cell death by beta(2)-adrenergic signaling in adult mouse cardiac myocytesCardiac signaling genes exhibit unexpected sequence diversity in sporadic cardiomyopathy, revealing HSPB7 polymorphisms associated with diseaseEffect of rare variants in ADRB2 on risk of severe exacerbations and symptom control during longacting β agonist treatment in a multiethnic asthma population: a genetic study.Rescue of familial cardiomyopathies by modifications at the level of sarcomere and Ca2+ fluxes.Enhancement of cardiac function after adenoviral-mediated in vivo intracoronary beta2-adrenergic receptor gene deliverybeta(2)-adrenergic receptor pharmacogenetics.A four amino acid deletion polymorphism in the third intracellular loop of the human alpha 2C-adrenergic receptor confers impaired coupling to multiple effectors.RAAS and adrenergic genes in heart failure: Function, predisposition and survival implicationsBeta-adrenergic signaling in the heart: dual coupling of the beta2-adrenergic receptor to G(s) and G(i) proteins.Role of race in the pharmacotherapy of heart failure.Haplotype analysis of the beta2 adrenergic receptor gene and risk of myocardial infarction in humans.Comprehensive biochemical analysis of rare prostacyclin receptor variants: study of association of signaling with coronary artery obstruction.Beta 1- and beta 2-adrenoceptor polymorphisms and cardiovascular diseases.Genes and their polymorphisms in mono- and multifactorial cardiomyopathies: towards pharmacogenomics in heart failure.Very important pharmacogene summary ADRB2.The genomic architecture of sporadic heart failurePharmacogenetics in drug regulation: promise, potential and pitfalls.The effect of Gi-protein inactivation on basal, and beta(1)- and beta(2)AR-stimulated contraction of myocytes from transgenic mice overexpressing the beta(2)-adrenoceptor.Emerging therapeutic targets in chronic heart failure: part II.Targeting signaling pathways in heart failure by gene transfer.Genetics and heart failure: a concise guide for the clinicianGenetic variation, β-blockers, and perioperative myocardial infarction.Drug development and use in the elderly: search for the right dose and dosing regimen (Parts I and II).No positive association between adrenergic receptor variants of alpha2cDel322-325, beta1Ser49, beta1Arg389 and the risk for heart failure in the Japanese populationPharmacogenomics of adrenoceptors.Genetic polymorphisms and heart failure.Thr164Ile polymorphism of beta2-adrenergic receptor negatively modulates cardiac contractility: implications for prognosis in patients with idiopathic dilated cardiomyopathy.Mechanistic basis of adverse drug reactions: the perils of inappropriate dose schedules.Genetics of asthma susceptibility and severityAdrenoceptor polymorphisms and the risk of cardiac injury and dysfunction after subarachnoid hemorrhage.The G protein-coupled receptors: pharmacogenetics and disease.Biased β2-adrenoceptor signalling in heart failure: pathophysiology and drug discovery.Genetic mutations and mechanisms in dilated cardiomyopathyFrom evidence-based medicine to genomic medicine.Neurohumoral activation in heart failure: the role of adrenergic receptors.The role of adrenergic receptor polymorphisms in heart failure.
P2860
Q24290107-125E146E-C5BD-46BF-A7E2-A74594898BCCQ26852239-778EA60F-1878-44B2-A31A-6250A719729BQ28367889-2A0C6CD5-18CD-4255-A780-1CD11810E723Q30877320-BBBE77AD-8DF5-4AEE-B914-61E3438E48DFQ33181618-BB3D427D-2895-4487-BFFB-BB1BC4877AC6Q33559617-739BD37D-AF3B-4731-9EDC-9A40FC5ABE69Q33739535-6177C503-2E00-4CA7-B59A-D592C7A9D51FQ33787794-992767BA-10A8-4CEB-AB47-A4E72A9072DBQ33853399-968E73B1-FF43-43C8-BBAD-4385B04BC1DAQ33860287-00514F39-61FB-47C4-9D6A-CFA98E223BEDQ33901100-55B7457E-AC83-4346-A63E-0856C3C0FCAFQ34390058-AF625433-0BDD-4576-9CF6-E89E0B5430B3Q34403963-DCD8EC37-B208-4D4A-BEFD-EE9469F4E8F9Q34564305-F2AD6889-1BAB-45E1-8245-D3CA83837466Q34572419-E9A065F1-72C4-4CC3-8808-D6910B022BD5Q34606153-4AA9CF18-A331-456D-8910-28897BA35CE1Q34658477-032118C2-C441-4438-9C7E-3FDE3DD570E1Q34673385-15F80016-70D6-4D57-BBCD-FDAC0C5DF561Q34994884-4FC8A43C-7290-4A9E-B52D-D7BA88181C4DQ35033305-D0BD9144-A8D0-4BA5-99F6-E402074B0263Q35038052-FA819E37-15FC-44F4-BC7A-E288BEFFFFA4Q35042735-F5C68D61-53A0-476F-A2BE-72BB68F67F28Q35056026-558552EA-2F83-489C-85DD-E57F1CAD888BQ35095401-24114362-4C81-49DA-8E26-BFCFF1216A0CQ35139937-CA1AC51F-FDE4-42DB-91D6-02575ABF64C6Q35580952-47627430-9805-40A3-AE96-ED40FC1DD7EBQ35826495-4E6CD589-5541-4ACD-9BCD-2403906C4E51Q35826919-5D2DD60C-D87E-4AB6-BF5B-B52B928B8685Q35911140-AEB87C9F-FDE0-406A-B1B8-C22C9619D83EQ35951357-6828396A-5EA8-49B7-80F8-C1F47BFD6A83Q36014089-D86AFE53-0DBC-44E7-979C-F18682E8B98BQ36040772-8EF5DB40-532D-4F07-82E3-E1C39F8E8CF1Q36201283-6665737D-E8E3-4121-85A2-D411A1AB4AE7Q36304329-9470F745-C089-40C6-8606-0C174B042F48Q36310854-59257147-7009-48EF-A74F-169F992057B4Q36342091-A8A46F63-B3D9-4188-B1FD-EFB27A4CC559Q36497170-88D99E9A-3F87-4295-A680-1617C94701C4Q36499873-0B31DE54-F3D9-46A5-87E8-B27A870AC585Q36579463-96406075-9135-4792-B3C7-B40F09DE30C9Q36629879-58041007-E614-4A24-B5AB-203E1E288199
P2860
The Ile164 beta2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 1998
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The Ile164 beta2-adrenergic re ...... e of congestive heart failure.
@en
The Ile164 beta2-adrenergic re ...... e of congestive heart failure.
@nl
type
label
The Ile164 beta2-adrenergic re ...... e of congestive heart failure.
@en
The Ile164 beta2-adrenergic re ...... e of congestive heart failure.
@nl
prefLabel
The Ile164 beta2-adrenergic re ...... e of congestive heart failure.
@en
The Ile164 beta2-adrenergic re ...... e of congestive heart failure.
@nl
P2093
P2860
P356
P1476
The Ile164 beta2-adrenergic re ...... e of congestive heart failure.
@en
P2093
L E Wagoner
R W Hornung
S B Liggett
T C McIntosh
P2860
P304
P356
10.1172/JCI4059
P407
P577
1998-10-01T00:00:00Z